On July 19, 2021, Shenzhen Evergreen Therapeutics Co., Ltd. announced the appointment of Dr. Charles Lee as the Company's Chief Medical Officer (CMO) with overall responsibility for the Company's global drug development efforts. Dr. Lee's joining will further improve the research team building, build a more efficient clinical trial medicine system, greatly promote the progress of clinical research projects, and accelerate the leap-forward development of the company.
Dr. Lee graduated from the School of Medicine of Xi 'an Jiaotong University, received his master's degree in hospital management and his doctor's degree in public health from the University of Alabama at Birmingham, USA. He worked as a resident physician at the University of Chicago Medical Center for three years, and was licensed as a physician in the United States and certified as a clinical pathologist. Dr. Lee was a senior medical reviewer of the US Food and Drug Administration (FDA), and was the first person from mainland China who studied abroad to enter FDA clinical review as a doctor. He has experience in FDA drug review and has led the development of new drugs for a number of multinational pharmaceutical companies and achieved profitable business growth. In the past four years, he is responsible for an international CRO giant in Asia Pacific, clinical, laws and regulations, market access, such as consulting, seven countries/regions in the Asia-pacific region the leadership of the team, direct management and participate in every year hundreds of R&D strategy consulting projects and help international companies of drug approval and successfully listed in China, to help domestic companies to develop global research plans to enter the international market. Dr. Lee has extensive experience in the development of new drugs in oncology, immunotherapy, anti-inflammatory, gastrointestinal and gynecological diseases, and has extensive experience in Phase I to IV clinical trials worldwide. He has led hundreds of clinical trials and more than 30 new drug applications worldwide and has the ability to develop overall solutions for global drug development, regulatory registration, clinical strategy and risk management. In addition, he has extensive experience working with global drug regulatory agencies (FDA, EMEA, MHRA, Health Canada, PMDA, DCGI [India] and NMPA [China]).
Dr. Lee said:
"I am very pleased to join Evergreen Shenzhen, a company co-founded by a number of former FDA partners and a distinguished group of investors. I will work with all my colleagues in the company to serve the society and patients for the purpose of focusing on the "three first". That is, "indication priority, treatment choice priority, and first-in-patient focus", through the innovation of clinical value development, clinical treatment practice and patient needs, we will lead the new development of the company's business and realize the take-off of the company.
Dr. Tom Du, Chairman of Evergreen Therapeutics, said:
"We would like to welcome Dr. Le to join the Shenzhen Evergreen Therapeutics team. Dr. Lee is not only a friend of mine for many years, but also a medical expert whom I admire very much. In addition to his work experience in FDA, he has a complete resume of medical director of medicine, senior director of clinical research and development, clinical vice president and vice president of regulation of large companies in the pharmaceutical industry, as well as his work experience in new drug development strategy. He has profound attainments in clinical trial design and clinical trial execution. Dr. Lee will be a member of the core team to lead the company's global drug development, and his joining will contribute to Evergreen's sustained and long-term growth."
About Evergreen Therapeutics:
Evergreen Therapeutics is an innovative pharmaceutical company founded by a number of former FDA senior reviewer and more than a dozen former executives of multinational pharmaceutical companies. Evergreen focuses on the research and development of therapeutic drugs with urgent clinical needs, and focuses on the clinical research, development and commercialization of innovative drugs. In 2020, Evergreen Pharma has received three FDA clinical trial approvals. In March 2021, Evergreen coordinated with a number of institutional investors and completed a round of financing of RMB 100 million. Evergreen is currently developing more than 10 drug candidates, including three that are in Phase I to Phase IV clinical trials.
For more information about Evergreen, please visit our website: http://www.egpharm.com/